Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kenneth C Anderson

Showing results (331-340 of 868) with videos related to

Pageof 87
Sort By:
British Journal of Haematology|September 14, 2012
Methyljasmonate displays in vitro and in vivo activity against multiple myeloma cellsSteffen Klippel, Jana Jakubikova, Jake Delmore, et al.
Proceedings of the National Academy of Sciences of the United States of America|August 1, 2012
Pathological crystallization of human immunoglobulinsYing Wang, Aleksey Lomakin, Teru Hideshima, et al.
Blood Advances|May 1, 2025
Targeting Siglec-Sialic Acid Checkpoint to Reverse Immune Dysfunction Mediated by Plasmacytoid Dendritic Cells in MyelomaArghya Ray, Leutz Buon, Xueping Wan, et al.
British Journal of Haematology|May 11, 2016
Marizomib irreversibly inhibits proteasome to overcome compensatory hyperactivation in multiple myeloma and solid tumour patientsNancy Levin, Andrew Spencer, Simon J Harrison, et al.
Cancer Research|October 20, 2004
Caveolin-1 is required for vascular endothelial growth factor-triggered multiple myeloma cell migration and is targeted by bortezomibKlaus Podar, Reshma Shringarpure, Yu-Tzu Tai, et al.
Blood|May 31, 2002
Apoptotic signaling induced by immunomodulatory thalidomide analogs in human multiple myeloma cells: therapeutic implicationsNicholas Mitsiades, Constantine S Mitsiades, Vassiliki Poulaki, et al.
Oncoimmunology|May 6, 2015
Heteroclitic XBP1 peptides evoke tumor-specific memory cytotoxic T lymphocytes against breast cancer, colon cancer, and pancreatic cancer cellsJooeun Bae, Mehmet Samur, Aditya Munshi, et al.
Cancer Management and Research|December 29, 2010
Bortezomib in the management of multiple myelomaJacob P Laubach, Constantine S Mitsiades, Teru Hideshima, et al.
British Journal of Haematology|January 11, 2005
Molecular mechanisms whereby immunomodulatory drugs activate natural killer cells: clinical applicationToshiaki Hayashi, Teru Hideshima, Masaharu Akiyama, et al.
Leukemia|July 21, 2018
A genome-scale CRISPR-Cas9 screening in myeloma cells identifies regulators of immunomodulatory drug sensitivityJiye Liu, Tianyu Song, Wenrong Zhou, et al.
Pageof 87

Showing results (331-340 of 868) with videos related to

Sort By:
Pageof 87
British Journal of Haematology|September 14, 2012
Methyljasmonate displays in vitro and in vivo activity against multiple myeloma cellsSteffen Klippel, Jana Jakubikova, Jake Delmore, et al.
Proceedings of the National Academy of Sciences of the United States of America|August 1, 2012
Pathological crystallization of human immunoglobulinsYing Wang, Aleksey Lomakin, Teru Hideshima, et al.
Blood Advances|May 1, 2025
Targeting Siglec-Sialic Acid Checkpoint to Reverse Immune Dysfunction Mediated by Plasmacytoid Dendritic Cells in MyelomaArghya Ray, Leutz Buon, Xueping Wan, et al.
British Journal of Haematology|May 11, 2016
Marizomib irreversibly inhibits proteasome to overcome compensatory hyperactivation in multiple myeloma and solid tumour patientsNancy Levin, Andrew Spencer, Simon J Harrison, et al.
Cancer Research|October 20, 2004
Caveolin-1 is required for vascular endothelial growth factor-triggered multiple myeloma cell migration and is targeted by bortezomibKlaus Podar, Reshma Shringarpure, Yu-Tzu Tai, et al.
Blood|May 31, 2002
Apoptotic signaling induced by immunomodulatory thalidomide analogs in human multiple myeloma cells: therapeutic implicationsNicholas Mitsiades, Constantine S Mitsiades, Vassiliki Poulaki, et al.
Oncoimmunology|May 6, 2015
Heteroclitic XBP1 peptides evoke tumor-specific memory cytotoxic T lymphocytes against breast cancer, colon cancer, and pancreatic cancer cellsJooeun Bae, Mehmet Samur, Aditya Munshi, et al.
Cancer Management and Research|December 29, 2010
Bortezomib in the management of multiple myelomaJacob P Laubach, Constantine S Mitsiades, Teru Hideshima, et al.
British Journal of Haematology|January 11, 2005
Molecular mechanisms whereby immunomodulatory drugs activate natural killer cells: clinical applicationToshiaki Hayashi, Teru Hideshima, Masaharu Akiyama, et al.
Leukemia|July 21, 2018
A genome-scale CRISPR-Cas9 screening in myeloma cells identifies regulators of immunomodulatory drug sensitivityJiye Liu, Tianyu Song, Wenrong Zhou, et al.
Pageof 87